RxDoctor Payments DataLook up a doctor →

Samuel Goldlust, MD

Neurology · Kansas City, MONPI 1225221922

Payments from drug & device makers

$1,678,844in general payments, 2019–2025

Across 368 payments — averaging $4562.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Karyopharm Therapeutics Inc.$1.1M
  • Novocure Inc.$271K
  • Novocure GmbH$184K
  • E.r. Squibb & Sons, L.L.C.$105K
  • Celularity Inc.$30K
  • Veloxis Pharmaceuticals, Inc.$22K
  • plus $8K from 6 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,678,844 in reported general payments places this provider in the 95th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$47,990
Medicare patients
67
Services billed
413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →